nodes	percent_of_prediction	percent_of_DWPC	metapath
Gliclazide—VEGFA—melanoma	0.51	0.788	CbGaD
Gliclazide—ALB—melanoma	0.137	0.212	CbGaD
Gliclazide—ALB—Vemurafenib—melanoma	0.044	1	CbGbCtD
Gliclazide—Chlorpropamide—SLC15A2—melanoma	0.00102	0.254	CrCbGaD
Gliclazide—Tolbutamide—SLC15A2—melanoma	0.000998	0.248	CrCbGaD
Gliclazide—Glipizide—PPARG—melanoma	0.000811	0.201	CrCbGaD
Gliclazide—Glyburide—SLC15A2—melanoma	0.000692	0.172	CrCbGaD
Gliclazide—Erythema multiforme—Dactinomycin—melanoma	0.000298	0.00212	CcSEcCtD
Gliclazide—Sinusitis—Temozolomide—melanoma	0.000298	0.00212	CcSEcCtD
Gliclazide—Erythema—Bleomycin—melanoma	0.000294	0.00209	CcSEcCtD
Gliclazide—Hypoaesthesia—Carmustine—melanoma	0.000294	0.00209	CcSEcCtD
Gliclazide—Flushing—Dactinomycin—melanoma	0.000293	0.00208	CcSEcCtD
Gliclazide—Hypersensitivity—Vemurafenib—melanoma	0.000292	0.00208	CcSEcCtD
Gliclazide—Oedema peripheral—Carmustine—melanoma	0.000291	0.00207	CcSEcCtD
Gliclazide—Visual disturbance—Docetaxel—melanoma	0.000289	0.00206	CcSEcCtD
Gliclazide—Renal impairment—Docetaxel—melanoma	0.000288	0.00205	CcSEcCtD
Gliclazide—Hepatitis—Temozolomide—melanoma	0.000285	0.00203	CcSEcCtD
Gliclazide—Asthenia—Vemurafenib—melanoma	0.000284	0.00202	CcSEcCtD
Gliclazide—Visual impairment—Carmustine—melanoma	0.000284	0.00202	CcSEcCtD
Gliclazide—Hypoaesthesia—Temozolomide—melanoma	0.000284	0.00202	CcSEcCtD
Gliclazide—Pharyngitis—Temozolomide—melanoma	0.000283	0.00201	CcSEcCtD
Gliclazide—Chills—Dactinomycin—melanoma	0.000283	0.00201	CcSEcCtD
Gliclazide—Oedema peripheral—Temozolomide—melanoma	0.000281	0.002	CcSEcCtD
Gliclazide—Cardiac failure—Docetaxel—melanoma	0.000281	0.002	CcSEcCtD
Gliclazide—Pruritus—Vemurafenib—melanoma	0.000281	0.00199	CcSEcCtD
Gliclazide—Eye disorder—Carmustine—melanoma	0.000276	0.00196	CcSEcCtD
Gliclazide—Hyponatraemia—Docetaxel—melanoma	0.000275	0.00196	CcSEcCtD
Gliclazide—Visual impairment—Temozolomide—melanoma	0.000275	0.00195	CcSEcCtD
Gliclazide—Erythema—Dactinomycin—melanoma	0.000275	0.00195	CcSEcCtD
Gliclazide—Pain in extremity—Docetaxel—melanoma	0.000274	0.00195	CcSEcCtD
Gliclazide—Gastrointestinal haemorrhage—Docetaxel—melanoma	0.000274	0.00195	CcSEcCtD
Gliclazide—Flushing—Carmustine—melanoma	0.000274	0.00195	CcSEcCtD
Gliclazide—Ill-defined disorder—Bleomycin—melanoma	0.000273	0.00194	CcSEcCtD
Gliclazide—Anaemia—Bleomycin—melanoma	0.000272	0.00193	CcSEcCtD
Gliclazide—Diarrhoea—Vemurafenib—melanoma	0.000271	0.00193	CcSEcCtD
Gliclazide—Erythema multiforme—Temozolomide—melanoma	0.00027	0.00192	CcSEcCtD
Gliclazide—Eye disorder—Temozolomide—melanoma	0.000267	0.00189	CcSEcCtD
Gliclazide—Tinnitus—Temozolomide—melanoma	0.000266	0.00189	CcSEcCtD
Gliclazide—Malaise—Bleomycin—melanoma	0.000265	0.00189	CcSEcCtD
Gliclazide—Flushing—Temozolomide—melanoma	0.000265	0.00188	CcSEcCtD
Gliclazide—Arrhythmia—Carmustine—melanoma	0.000264	0.00187	CcSEcCtD
Gliclazide—Leukopenia—Bleomycin—melanoma	0.000263	0.00187	CcSEcCtD
Gliclazide—Dizziness—Vemurafenib—melanoma	0.000262	0.00186	CcSEcCtD
Gliclazide—Mental disorder—Carmustine—melanoma	0.000259	0.00184	CcSEcCtD
Gliclazide—Erythema—Carmustine—melanoma	0.000257	0.00183	CcSEcCtD
Gliclazide—Malnutrition—Carmustine—melanoma	0.000257	0.00183	CcSEcCtD
Gliclazide—Cough—Bleomycin—melanoma	0.000257	0.00183	CcSEcCtD
Gliclazide—Chills—Temozolomide—melanoma	0.000256	0.00182	CcSEcCtD
Gliclazide—Ill-defined disorder—Dactinomycin—melanoma	0.000255	0.00181	CcSEcCtD
Gliclazide—Anaemia—Dactinomycin—melanoma	0.000254	0.0018	CcSEcCtD
Gliclazide—Vomiting—Vemurafenib—melanoma	0.000252	0.00179	CcSEcCtD
Gliclazide—Dry skin—Docetaxel—melanoma	0.000251	0.00179	CcSEcCtD
Gliclazide—Chest pain—Bleomycin—melanoma	0.000251	0.00178	CcSEcCtD
Gliclazide—Myalgia—Bleomycin—melanoma	0.000251	0.00178	CcSEcCtD
Gliclazide—Rash—Vemurafenib—melanoma	0.00025	0.00178	CcSEcCtD
Gliclazide—Mental disorder—Temozolomide—melanoma	0.00025	0.00178	CcSEcCtD
Gliclazide—Dermatitis—Vemurafenib—melanoma	0.00025	0.00177	CcSEcCtD
Gliclazide—Back pain—Carmustine—melanoma	0.000249	0.00177	CcSEcCtD
Gliclazide—Headache—Vemurafenib—melanoma	0.000248	0.00177	CcSEcCtD
Gliclazide—Erythema—Temozolomide—melanoma	0.000248	0.00176	CcSEcCtD
Gliclazide—Malnutrition—Temozolomide—melanoma	0.000248	0.00176	CcSEcCtD
Gliclazide—Discomfort—Bleomycin—melanoma	0.000248	0.00176	CcSEcCtD
Gliclazide—Malaise—Dactinomycin—melanoma	0.000248	0.00176	CcSEcCtD
Gliclazide—Toxic epidermal necrolysis—Docetaxel—melanoma	0.000247	0.00175	CcSEcCtD
Gliclazide—Leukopenia—Dactinomycin—melanoma	0.000246	0.00175	CcSEcCtD
Gliclazide—Confusional state—Bleomycin—melanoma	0.000242	0.00172	CcSEcCtD
Gliclazide—Tremor—Carmustine—melanoma	0.000241	0.00171	CcSEcCtD
Gliclazide—Back pain—Temozolomide—melanoma	0.00024	0.00171	CcSEcCtD
Gliclazide—Infection—Bleomycin—melanoma	0.000239	0.0017	CcSEcCtD
Gliclazide—Anaemia—Carmustine—melanoma	0.000237	0.00169	CcSEcCtD
Gliclazide—Agitation—Carmustine—melanoma	0.000236	0.00168	CcSEcCtD
Gliclazide—Nausea—Vemurafenib—melanoma	0.000236	0.00167	CcSEcCtD
Gliclazide—Thrombocytopenia—Bleomycin—melanoma	0.000235	0.00167	CcSEcCtD
Gliclazide—Myalgia—Dactinomycin—melanoma	0.000234	0.00166	CcSEcCtD
Gliclazide—Tremor—Temozolomide—melanoma	0.000233	0.00165	CcSEcCtD
Gliclazide—Discomfort—Dactinomycin—melanoma	0.000231	0.00164	CcSEcCtD
Gliclazide—Angina pectoris—Docetaxel—melanoma	0.000231	0.00164	CcSEcCtD
Gliclazide—Ill-defined disorder—Temozolomide—melanoma	0.00023	0.00164	CcSEcCtD
Gliclazide—Leukopenia—Carmustine—melanoma	0.00023	0.00163	CcSEcCtD
Gliclazide—Anaemia—Temozolomide—melanoma	0.000229	0.00163	CcSEcCtD
Gliclazide—Agitation—Temozolomide—melanoma	0.000228	0.00162	CcSEcCtD
Gliclazide—Angioedema—Temozolomide—melanoma	0.000227	0.00161	CcSEcCtD
Gliclazide—Pancytopenia—Docetaxel—melanoma	0.000225	0.0016	CcSEcCtD
Gliclazide—Hypotension—Bleomycin—melanoma	0.000224	0.0016	CcSEcCtD
Gliclazide—Malaise—Temozolomide—melanoma	0.000224	0.00159	CcSEcCtD
Gliclazide—Convulsion—Carmustine—melanoma	0.000223	0.00158	CcSEcCtD
Gliclazide—Infection—Dactinomycin—melanoma	0.000223	0.00158	CcSEcCtD
Gliclazide—Leukopenia—Temozolomide—melanoma	0.000222	0.00158	CcSEcCtD
Gliclazide—Hypertension—Carmustine—melanoma	0.000222	0.00158	CcSEcCtD
Gliclazide—Palpitations—Temozolomide—melanoma	0.000219	0.00156	CcSEcCtD
Gliclazide—Thrombocytopenia—Dactinomycin—melanoma	0.000219	0.00156	CcSEcCtD
Gliclazide—Musculoskeletal discomfort—Bleomycin—melanoma	0.000219	0.00156	CcSEcCtD
Gliclazide—Chest pain—Carmustine—melanoma	0.000219	0.00155	CcSEcCtD
Gliclazide—Myalgia—Carmustine—melanoma	0.000219	0.00155	CcSEcCtD
Gliclazide—Anxiety—Carmustine—melanoma	0.000218	0.00155	CcSEcCtD
Gliclazide—Cough—Temozolomide—melanoma	0.000217	0.00154	CcSEcCtD
Gliclazide—Paraesthesia—Bleomycin—melanoma	0.000216	0.00153	CcSEcCtD
Gliclazide—Weight increased—Docetaxel—melanoma	0.000216	0.00153	CcSEcCtD
Gliclazide—Convulsion—Temozolomide—melanoma	0.000215	0.00153	CcSEcCtD
Gliclazide—Hypertension—Temozolomide—melanoma	0.000214	0.00152	CcSEcCtD
Gliclazide—Dyspnoea—Bleomycin—melanoma	0.000214	0.00152	CcSEcCtD
Gliclazide—Pneumonia—Docetaxel—melanoma	0.000213	0.00151	CcSEcCtD
Gliclazide—Confusional state—Carmustine—melanoma	0.000211	0.0015	CcSEcCtD
Gliclazide—Myalgia—Temozolomide—melanoma	0.000211	0.0015	CcSEcCtD
Gliclazide—Arthralgia—Temozolomide—melanoma	0.000211	0.0015	CcSEcCtD
Gliclazide—Anxiety—Temozolomide—melanoma	0.000211	0.0015	CcSEcCtD
Gliclazide—Chlorpropamide—ABCB1—melanoma	0.00021	0.0522	CrCbGaD
Gliclazide—Unspecified disorder of skin and subcutaneous tissue—Temozolomide—melanoma	0.00021	0.00149	CcSEcCtD
Gliclazide—Stevens-Johnson syndrome—Docetaxel—melanoma	0.000209	0.00149	CcSEcCtD
Gliclazide—Discomfort—Temozolomide—melanoma	0.000209	0.00148	CcSEcCtD
Gliclazide—Infection—Carmustine—melanoma	0.000208	0.00148	CcSEcCtD
Gliclazide—Acute coronary syndrome—Docetaxel—melanoma	0.000208	0.00148	CcSEcCtD
Gliclazide—Renal failure—Docetaxel—melanoma	0.000208	0.00148	CcSEcCtD
Gliclazide—Myocardial infarction—Docetaxel—melanoma	0.000207	0.00147	CcSEcCtD
Gliclazide—Neuropathy peripheral—Docetaxel—melanoma	0.000207	0.00147	CcSEcCtD
Gliclazide—Dry mouth—Temozolomide—melanoma	0.000207	0.00147	CcSEcCtD
Gliclazide—Jaundice—Docetaxel—melanoma	0.000206	0.00146	CcSEcCtD
Gliclazide—Pain—Bleomycin—melanoma	0.000205	0.00146	CcSEcCtD
Gliclazide—Conjunctivitis—Docetaxel—melanoma	0.000205	0.00146	CcSEcCtD
Gliclazide—Thrombocytopenia—Carmustine—melanoma	0.000205	0.00146	CcSEcCtD
Gliclazide—Tachycardia—Carmustine—melanoma	0.000205	0.00145	CcSEcCtD
Gliclazide—Confusional state—Temozolomide—melanoma	0.000204	0.00145	CcSEcCtD
Gliclazide—Musculoskeletal discomfort—Dactinomycin—melanoma	0.000204	0.00145	CcSEcCtD
Gliclazide—Infection—Temozolomide—melanoma	0.000201	0.00143	CcSEcCtD
Gliclazide—Hepatobiliary disease—Docetaxel—melanoma	0.0002	0.00142	CcSEcCtD
Gliclazide—Epistaxis—Docetaxel—melanoma	0.000199	0.00142	CcSEcCtD
Gliclazide—Nervous system disorder—Temozolomide—melanoma	0.000199	0.00141	CcSEcCtD
Gliclazide—Thrombocytopenia—Temozolomide—melanoma	0.000198	0.00141	CcSEcCtD
Gliclazide—Feeling abnormal—Bleomycin—melanoma	0.000198	0.00141	CcSEcCtD
Gliclazide—Agranulocytosis—Docetaxel—melanoma	0.000197	0.0014	CcSEcCtD
Gliclazide—Skin disorder—Temozolomide—melanoma	0.000197	0.0014	CcSEcCtD
Gliclazide—Hypotension—Carmustine—melanoma	0.000196	0.00139	CcSEcCtD
Gliclazide—Hyperhidrosis—Temozolomide—melanoma	0.000196	0.00139	CcSEcCtD
Gliclazide—Fatigue—Dactinomycin—melanoma	0.000193	0.00137	CcSEcCtD
Gliclazide—Pain—Dactinomycin—melanoma	0.000192	0.00136	CcSEcCtD
Gliclazide—Musculoskeletal discomfort—Carmustine—melanoma	0.000191	0.00136	CcSEcCtD
Gliclazide—Urticaria—Bleomycin—melanoma	0.000191	0.00136	CcSEcCtD
Gliclazide—Rhinitis—Docetaxel—melanoma	0.00019	0.00135	CcSEcCtD
Gliclazide—Body temperature increased—Bleomycin—melanoma	0.00019	0.00135	CcSEcCtD
Gliclazide—Hepatitis—Docetaxel—melanoma	0.00019	0.00135	CcSEcCtD
Gliclazide—Insomnia—Carmustine—melanoma	0.00019	0.00135	CcSEcCtD
Gliclazide—Hypoaesthesia—Docetaxel—melanoma	0.000189	0.00134	CcSEcCtD
Gliclazide—Paraesthesia—Carmustine—melanoma	0.000188	0.00134	CcSEcCtD
Gliclazide—Pharyngitis—Docetaxel—melanoma	0.000188	0.00134	CcSEcCtD
Gliclazide—Dyspnoea—Carmustine—melanoma	0.000187	0.00133	CcSEcCtD
Gliclazide—Oedema peripheral—Docetaxel—melanoma	0.000187	0.00133	CcSEcCtD
Gliclazide—Somnolence—Carmustine—melanoma	0.000186	0.00132	CcSEcCtD
Gliclazide—Feeling abnormal—Dactinomycin—melanoma	0.000185	0.00131	CcSEcCtD
Gliclazide—Musculoskeletal discomfort—Temozolomide—melanoma	0.000185	0.00131	CcSEcCtD
Gliclazide—Insomnia—Temozolomide—melanoma	0.000183	0.0013	CcSEcCtD
Gliclazide—Gastrointestinal pain—Dactinomycin—melanoma	0.000183	0.0013	CcSEcCtD
Gliclazide—Visual impairment—Docetaxel—melanoma	0.000183	0.0013	CcSEcCtD
Gliclazide—Paraesthesia—Temozolomide—melanoma	0.000182	0.00129	CcSEcCtD
Gliclazide—Gastrointestinal disorder—Carmustine—melanoma	0.000181	0.00129	CcSEcCtD
Gliclazide—Dyspnoea—Temozolomide—melanoma	0.000181	0.00128	CcSEcCtD
Gliclazide—Somnolence—Temozolomide—melanoma	0.00018	0.00128	CcSEcCtD
Gliclazide—Erythema multiforme—Docetaxel—melanoma	0.000179	0.00127	CcSEcCtD
Gliclazide—Constipation—Carmustine—melanoma	0.000179	0.00127	CcSEcCtD
Gliclazide—Pain—Carmustine—melanoma	0.000179	0.00127	CcSEcCtD
Gliclazide—Dyspepsia—Temozolomide—melanoma	0.000178	0.00127	CcSEcCtD
Gliclazide—Eye disorder—Docetaxel—melanoma	0.000177	0.00126	CcSEcCtD
Gliclazide—Body temperature increased—Dactinomycin—melanoma	0.000177	0.00126	CcSEcCtD
Gliclazide—Abdominal pain—Dactinomycin—melanoma	0.000177	0.00126	CcSEcCtD
Gliclazide—Hypersensitivity—Bleomycin—melanoma	0.000177	0.00126	CcSEcCtD
Gliclazide—Flushing—Docetaxel—melanoma	0.000176	0.00125	CcSEcCtD
Gliclazide—Gastrointestinal disorder—Temozolomide—melanoma	0.000175	0.00124	CcSEcCtD
Gliclazide—Fatigue—Temozolomide—melanoma	0.000175	0.00124	CcSEcCtD
Gliclazide—Constipation—Temozolomide—melanoma	0.000173	0.00123	CcSEcCtD
Gliclazide—Pain—Temozolomide—melanoma	0.000173	0.00123	CcSEcCtD
Gliclazide—Feeling abnormal—Carmustine—melanoma	0.000173	0.00123	CcSEcCtD
Gliclazide—Asthenia—Bleomycin—melanoma	0.000172	0.00122	CcSEcCtD
Gliclazide—Gastrointestinal pain—Carmustine—melanoma	0.000171	0.00122	CcSEcCtD
Gliclazide—Chills—Docetaxel—melanoma	0.00017	0.00121	CcSEcCtD
Gliclazide—Pruritus—Bleomycin—melanoma	0.00017	0.00121	CcSEcCtD
Gliclazide—Arrhythmia—Docetaxel—melanoma	0.000169	0.0012	CcSEcCtD
Gliclazide—Feeling abnormal—Temozolomide—melanoma	0.000167	0.00119	CcSEcCtD
Gliclazide—Mental disorder—Docetaxel—melanoma	0.000166	0.00118	CcSEcCtD
Gliclazide—Abdominal pain—Carmustine—melanoma	0.000166	0.00118	CcSEcCtD
Gliclazide—Body temperature increased—Carmustine—melanoma	0.000166	0.00118	CcSEcCtD
Gliclazide—Gastrointestinal pain—Temozolomide—melanoma	0.000166	0.00118	CcSEcCtD
Gliclazide—Malnutrition—Docetaxel—melanoma	0.000165	0.00117	CcSEcCtD
Gliclazide—Erythema—Docetaxel—melanoma	0.000165	0.00117	CcSEcCtD
Gliclazide—Hypersensitivity—Dactinomycin—melanoma	0.000165	0.00117	CcSEcCtD
Gliclazide—Urticaria—Temozolomide—melanoma	0.000161	0.00114	CcSEcCtD
Gliclazide—Asthenia—Dactinomycin—melanoma	0.000161	0.00114	CcSEcCtD
Gliclazide—Abdominal pain—Temozolomide—melanoma	0.00016	0.00114	CcSEcCtD
Gliclazide—Body temperature increased—Temozolomide—melanoma	0.00016	0.00114	CcSEcCtD
Gliclazide—Back pain—Docetaxel—melanoma	0.00016	0.00113	CcSEcCtD
Gliclazide—Hypersensitivity—Carmustine—melanoma	0.000154	0.0011	CcSEcCtD
Gliclazide—Diarrhoea—Dactinomycin—melanoma	0.000153	0.00109	CcSEcCtD
Gliclazide—Vomiting—Bleomycin—melanoma	0.000153	0.00109	CcSEcCtD
Gliclazide—Anaemia—Docetaxel—melanoma	0.000153	0.00108	CcSEcCtD
Gliclazide—Rash—Bleomycin—melanoma	0.000151	0.00108	CcSEcCtD
Gliclazide—Dermatitis—Bleomycin—melanoma	0.000151	0.00108	CcSEcCtD
Gliclazide—Asthenia—Carmustine—melanoma	0.00015	0.00107	CcSEcCtD
Gliclazide—Hypersensitivity—Temozolomide—melanoma	0.000149	0.00106	CcSEcCtD
Gliclazide—Glyburide—ALB—melanoma	0.000149	0.037	CrCbGaD
Gliclazide—Leukopenia—Docetaxel—melanoma	0.000148	0.00105	CcSEcCtD
Gliclazide—Palpitations—Docetaxel—melanoma	0.000146	0.00104	CcSEcCtD
Gliclazide—Asthenia—Temozolomide—melanoma	0.000145	0.00103	CcSEcCtD
Gliclazide—Loss of consciousness—Docetaxel—melanoma	0.000145	0.00103	CcSEcCtD
Gliclazide—Cough—Docetaxel—melanoma	0.000144	0.00102	CcSEcCtD
Gliclazide—Diarrhoea—Carmustine—melanoma	0.000143	0.00102	CcSEcCtD
Gliclazide—Pruritus—Temozolomide—melanoma	0.000143	0.00102	CcSEcCtD
Gliclazide—Convulsion—Docetaxel—melanoma	0.000143	0.00102	CcSEcCtD
Gliclazide—Nausea—Bleomycin—melanoma	0.000143	0.00101	CcSEcCtD
Gliclazide—Hypertension—Docetaxel—melanoma	0.000143	0.00101	CcSEcCtD
Gliclazide—Vomiting—Dactinomycin—melanoma	0.000142	0.00101	CcSEcCtD
Gliclazide—Glyburide—ABCB1—melanoma	0.000142	0.0353	CrCbGaD
Gliclazide—Rash—Dactinomycin—melanoma	0.000141	0.001	CcSEcCtD
Gliclazide—Arthralgia—Docetaxel—melanoma	0.000141	0.000999	CcSEcCtD
Gliclazide—Myalgia—Docetaxel—melanoma	0.000141	0.000999	CcSEcCtD
Gliclazide—Chest pain—Docetaxel—melanoma	0.000141	0.000999	CcSEcCtD
Gliclazide—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—melanoma	0.00014	0.000992	CcSEcCtD
Gliclazide—Dizziness—Carmustine—melanoma	0.000139	0.000985	CcSEcCtD
Gliclazide—Diarrhoea—Temozolomide—melanoma	0.000139	0.000985	CcSEcCtD
Gliclazide—Dry mouth—Docetaxel—melanoma	0.000137	0.000977	CcSEcCtD
Gliclazide—Confusional state—Docetaxel—melanoma	0.000136	0.000966	CcSEcCtD
Gliclazide—Dizziness—Temozolomide—melanoma	0.000134	0.000952	CcSEcCtD
Gliclazide—Infection—Docetaxel—melanoma	0.000134	0.000951	CcSEcCtD
Gliclazide—Vomiting—Carmustine—melanoma	0.000133	0.000947	CcSEcCtD
Gliclazide—Nausea—Dactinomycin—melanoma	0.000133	0.000946	CcSEcCtD
Gliclazide—Rash—Carmustine—melanoma	0.000132	0.00094	CcSEcCtD
Gliclazide—Nervous system disorder—Docetaxel—melanoma	0.000132	0.000939	CcSEcCtD
Gliclazide—Dermatitis—Carmustine—melanoma	0.000132	0.000939	CcSEcCtD
Gliclazide—Thrombocytopenia—Docetaxel—melanoma	0.000132	0.000938	CcSEcCtD
Gliclazide—Tachycardia—Docetaxel—melanoma	0.000132	0.000935	CcSEcCtD
Gliclazide—Headache—Carmustine—melanoma	0.000131	0.000934	CcSEcCtD
Gliclazide—Skin disorder—Docetaxel—melanoma	0.000131	0.00093	CcSEcCtD
Gliclazide—Vomiting—Temozolomide—melanoma	0.000129	0.000916	CcSEcCtD
Gliclazide—Rash—Temozolomide—melanoma	0.000128	0.000908	CcSEcCtD
Gliclazide—Dermatitis—Temozolomide—melanoma	0.000128	0.000907	CcSEcCtD
Gliclazide—Headache—Temozolomide—melanoma	0.000127	0.000902	CcSEcCtD
Gliclazide—Hypotension—Docetaxel—melanoma	0.000126	0.000895	CcSEcCtD
Gliclazide—Nausea—Carmustine—melanoma	0.000125	0.000885	CcSEcCtD
Gliclazide—Musculoskeletal discomfort—Docetaxel—melanoma	0.000123	0.000872	CcSEcCtD
Gliclazide—Insomnia—Docetaxel—melanoma	0.000122	0.000866	CcSEcCtD
Gliclazide—Paraesthesia—Docetaxel—melanoma	0.000121	0.00086	CcSEcCtD
Gliclazide—Nausea—Temozolomide—melanoma	0.00012	0.000855	CcSEcCtD
Gliclazide—Dyspnoea—Docetaxel—melanoma	0.00012	0.000854	CcSEcCtD
Gliclazide—Somnolence—Docetaxel—melanoma	0.00012	0.000851	CcSEcCtD
Gliclazide—Dyspepsia—Docetaxel—melanoma	0.000119	0.000843	CcSEcCtD
Gliclazide—Gastrointestinal disorder—Docetaxel—melanoma	0.000116	0.000827	CcSEcCtD
Gliclazide—Fatigue—Docetaxel—melanoma	0.000116	0.000826	CcSEcCtD
Gliclazide—Constipation—Docetaxel—melanoma	0.000115	0.000819	CcSEcCtD
Gliclazide—Pain—Docetaxel—melanoma	0.000115	0.000819	CcSEcCtD
Gliclazide—Feeling abnormal—Docetaxel—melanoma	0.000111	0.000789	CcSEcCtD
Gliclazide—Gastrointestinal pain—Docetaxel—melanoma	0.00011	0.000783	CcSEcCtD
Gliclazide—Abdominal pain—Docetaxel—melanoma	0.000107	0.000757	CcSEcCtD
Gliclazide—Body temperature increased—Docetaxel—melanoma	0.000107	0.000757	CcSEcCtD
Gliclazide—Hypersensitivity—Docetaxel—melanoma	9.93e-05	0.000706	CcSEcCtD
Gliclazide—Asthenia—Docetaxel—melanoma	9.67e-05	0.000687	CcSEcCtD
Gliclazide—Pruritus—Docetaxel—melanoma	9.53e-05	0.000678	CcSEcCtD
Gliclazide—Diarrhoea—Docetaxel—melanoma	9.22e-05	0.000655	CcSEcCtD
Gliclazide—Dizziness—Docetaxel—melanoma	8.91e-05	0.000633	CcSEcCtD
Gliclazide—Vomiting—Docetaxel—melanoma	8.57e-05	0.000609	CcSEcCtD
Gliclazide—Rash—Docetaxel—melanoma	8.5e-05	0.000604	CcSEcCtD
Gliclazide—Dermatitis—Docetaxel—melanoma	8.49e-05	0.000603	CcSEcCtD
Gliclazide—Headache—Docetaxel—melanoma	8.44e-05	0.0006	CcSEcCtD
Gliclazide—Nausea—Docetaxel—melanoma	8e-05	0.000569	CcSEcCtD
Gliclazide—ALB—Hemostasis—IFNA2—melanoma	1.86e-05	0.000113	CbGpPWpGaD
Gliclazide—ALB—Transmembrane transport of small molecules—SLC5A5—melanoma	1.85e-05	0.000112	CbGpPWpGaD
Gliclazide—ALB—Metabolism—MTAP—melanoma	1.85e-05	0.000112	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—ITGAV—melanoma	1.83e-05	0.000111	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—AKT3—melanoma	1.83e-05	0.000111	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—NGFR—melanoma	1.83e-05	0.000111	CbGpPWpGaD
Gliclazide—KCNJ11—Metabolism—PRKCA—melanoma	1.83e-05	0.000111	CbGpPWpGaD
Gliclazide—VEGFA—Developmental Biology—MAPK1—melanoma	1.83e-05	0.000111	CbGpPWpGaD
Gliclazide—VEGFA—Developmental Biology—EGFR—melanoma	1.83e-05	0.000111	CbGpPWpGaD
Gliclazide—KCNJ11—Metabolism—ERCC2—melanoma	1.82e-05	0.00011	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—PLCB4—melanoma	1.81e-05	0.00011	CbGpPWpGaD
Gliclazide—ALB—Metabolism of lipids and lipoproteins—CYP1B1—melanoma	1.8e-05	0.00011	CbGpPWpGaD
Gliclazide—VEGFA—Hemostasis—MAPK1—melanoma	1.79e-05	0.000109	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism of lipids and lipoproteins—FASN—melanoma	1.78e-05	0.000108	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism of lipids and lipoproteins—CYP17A1—melanoma	1.75e-05	0.000107	CbGpPWpGaD
Gliclazide—ALB—Platelet activation, signaling and aggregation—PIK3CB—melanoma	1.75e-05	0.000106	CbGpPWpGaD
Gliclazide—VEGFA—Developmental Biology—TNF—melanoma	1.74e-05	0.000106	CbGpPWpGaD
Gliclazide—ALB—Hemostasis—ITGB1—melanoma	1.73e-05	0.000105	CbGpPWpGaD
Gliclazide—VEGFA—Developmental Biology—KRAS—melanoma	1.73e-05	0.000105	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—SLC6A11—melanoma	1.7e-05	0.000103	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—PIP4K2A—melanoma	1.7e-05	0.000103	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—SOCS1—melanoma	1.7e-05	0.000103	CbGpPWpGaD
Gliclazide—VEGFA—Hemostasis—KRAS—melanoma	1.69e-05	0.000103	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—S100B—melanoma	1.69e-05	0.000103	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—MTAP—melanoma	1.66e-05	0.000101	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—PLCB4—melanoma	1.65e-05	0.0001	CbGpPWpGaD
Gliclazide—ALB—Metabolism—LUM—melanoma	1.64e-05	9.99e-05	CbGpPWpGaD
Gliclazide—ALB—Metabolism—PHGDH—melanoma	1.64e-05	9.99e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism of lipids and lipoproteins—FASN—melanoma	1.62e-05	9.84e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism of lipids and lipoproteins—CYP1B1—melanoma	1.62e-05	9.83e-05	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—ERBB4—melanoma	1.62e-05	9.83e-05	CbGpPWpGaD
Gliclazide—ALB—Metabolism—HPSE—melanoma	1.61e-05	9.8e-05	CbGpPWpGaD
Gliclazide—ALB—Platelet activation, signaling and aggregation—IL2—melanoma	1.61e-05	9.75e-05	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—CDKN2B—melanoma	1.6e-05	9.74e-05	CbGpPWpGaD
Gliclazide—ALB—Hemostasis—HGF—melanoma	1.58e-05	9.62e-05	CbGpPWpGaD
Gliclazide—ALB—Metabolism—CUBN—melanoma	1.58e-05	9.62e-05	CbGpPWpGaD
Gliclazide—ALB—Hemostasis—CSF2—melanoma	1.57e-05	9.51e-05	CbGpPWpGaD
Gliclazide—VEGFA—Hemostasis—PIK3CA—melanoma	1.56e-05	9.45e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—PIP4K2A—melanoma	1.55e-05	9.43e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—SLC6A11—melanoma	1.55e-05	9.43e-05	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—CD86—melanoma	1.55e-05	9.42e-05	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—EDN1—melanoma	1.54e-05	9.35e-05	CbGpPWpGaD
Gliclazide—ALB—Metabolism—SDHD—melanoma	1.53e-05	9.29e-05	CbGpPWpGaD
Gliclazide—ALB—Metabolism—BSG—melanoma	1.53e-05	9.29e-05	CbGpPWpGaD
Gliclazide—ALB—Metabolism—CSPG4—melanoma	1.53e-05	9.29e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—MTAP—melanoma	1.51e-05	9.17e-05	CbGpPWpGaD
Gliclazide—VEGFA—Hemostasis—TP53—melanoma	1.51e-05	9.15e-05	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—CSF2—melanoma	1.5e-05	9.14e-05	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—FGF1—melanoma	1.5e-05	9.14e-05	CbGpPWpGaD
Gliclazide—ALB—Hemostasis—PRKCA—melanoma	1.5e-05	9.12e-05	CbGpPWpGaD
Gliclazide—ALB—Hemostasis—ITGB3—melanoma	1.5e-05	9.12e-05	CbGpPWpGaD
Gliclazide—ALB—Metabolism—GPAM—melanoma	1.48e-05	8.99e-05	CbGpPWpGaD
Gliclazide—ABCC8—Metabolism—PIK3CG—melanoma	1.48e-05	8.98e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—LUM—melanoma	1.48e-05	8.97e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—PHGDH—melanoma	1.48e-05	8.97e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism of lipids and lipoproteins—CYP1B1—melanoma	1.48e-05	8.97e-05	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—E2F1—melanoma	1.47e-05	8.94e-05	CbGpPWpGaD
Gliclazide—VEGFA—Developmental Biology—HRAS—melanoma	1.47e-05	8.92e-05	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—PDGFRA—melanoma	1.46e-05	8.85e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—HPSE—melanoma	1.45e-05	8.79e-05	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—ITGB3—melanoma	1.44e-05	8.76e-05	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—PRKCA—melanoma	1.44e-05	8.76e-05	CbGpPWpGaD
Gliclazide—VEGFA—Hemostasis—HRAS—melanoma	1.44e-05	8.75e-05	CbGpPWpGaD
Gliclazide—KCNJ11—Metabolism—PIK3CG—melanoma	1.43e-05	8.71e-05	CbGpPWpGaD
Gliclazide—ABCC8—Metabolism—PPARG—melanoma	1.43e-05	8.67e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—CUBN—melanoma	1.42e-05	8.63e-05	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—SPP1—melanoma	1.41e-05	8.59e-05	CbGpPWpGaD
Gliclazide—ALB—Transmembrane transport of small molecules—ABCB1—melanoma	1.41e-05	8.58e-05	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—MAP2K2—melanoma	1.41e-05	8.56e-05	CbGpPWpGaD
Gliclazide—VEGFA—Developmental Biology—IL6—melanoma	1.41e-05	8.53e-05	CbGpPWpGaD
Gliclazide—ALB—Hemostasis—RAC1—melanoma	1.39e-05	8.45e-05	CbGpPWpGaD
Gliclazide—KCNJ11—Metabolism—PPARG—melanoma	1.38e-05	8.41e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—SDHD—melanoma	1.37e-05	8.34e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—CSPG4—melanoma	1.37e-05	8.34e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—BSG—melanoma	1.37e-05	8.34e-05	CbGpPWpGaD
Gliclazide—ALB—Platelet activation, signaling and aggregation—VEGFA—melanoma	1.36e-05	8.29e-05	CbGpPWpGaD
Gliclazide—ALB—Hemostasis—MMP1—melanoma	1.35e-05	8.18e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—PHGDH—melanoma	1.35e-05	8.18e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—LUM—melanoma	1.35e-05	8.18e-05	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—TERT—melanoma	1.34e-05	8.14e-05	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—RAC1—melanoma	1.34e-05	8.12e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—GPAM—melanoma	1.33e-05	8.07e-05	CbGpPWpGaD
Gliclazide—ALB—Hemostasis—CDK2—melanoma	1.32e-05	8.03e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—HPSE—melanoma	1.32e-05	8.02e-05	CbGpPWpGaD
Gliclazide—ABCC8—Metabolism—PIK3CD—melanoma	1.3e-05	7.9e-05	CbGpPWpGaD
Gliclazide—VEGFA—Developmental Biology—AKT1—melanoma	1.3e-05	7.87e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—CUBN—melanoma	1.3e-05	7.87e-05	CbGpPWpGaD
Gliclazide—ALB—Platelet activation, signaling and aggregation—MAPK3—melanoma	1.29e-05	7.84e-05	CbGpPWpGaD
Gliclazide—ABCC8—Metabolism—ALB—melanoma	1.28e-05	7.79e-05	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—HIF1A—melanoma	1.28e-05	7.79e-05	CbGpPWpGaD
Gliclazide—VEGFA—Hemostasis—AKT1—melanoma	1.27e-05	7.72e-05	CbGpPWpGaD
Gliclazide—KCNJ11—Metabolism—PIK3CD—melanoma	1.26e-05	7.66e-05	CbGpPWpGaD
Gliclazide—ALB—Metabolism—PLA2G6—melanoma	1.26e-05	7.65e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—SDHD—melanoma	1.25e-05	7.6e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—BSG—melanoma	1.25e-05	7.6e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—CSPG4—melanoma	1.25e-05	7.6e-05	CbGpPWpGaD
Gliclazide—KCNJ11—Metabolism—ALB—melanoma	1.24e-05	7.56e-05	CbGpPWpGaD
Gliclazide—ALB—Hemostasis—FN1—melanoma	1.23e-05	7.46e-05	CbGpPWpGaD
Gliclazide—ALB—Platelet activation, signaling and aggregation—MAPK1—melanoma	1.23e-05	7.46e-05	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—KDR—melanoma	1.23e-05	7.45e-05	CbGpPWpGaD
Gliclazide—ALB—Hemostasis—NOS2—melanoma	1.21e-05	7.37e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—GPAM—melanoma	1.21e-05	7.36e-05	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—FN1—melanoma	1.18e-05	7.17e-05	CbGpPWpGaD
Gliclazide—ALB—Hemostasis—PIK3CG—melanoma	1.18e-05	7.14e-05	CbGpPWpGaD
Gliclazide—ALB—Hemostasis—EGF—melanoma	1.16e-05	7.06e-05	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—NOTCH1—melanoma	1.16e-05	7.02e-05	CbGpPWpGaD
Gliclazide—ABCC8—Metabolism—PIK3CB—melanoma	1.13e-05	6.88e-05	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—CD80—melanoma	1.13e-05	6.87e-05	CbGpPWpGaD
Gliclazide—ALB—Metabolism—VCAN—melanoma	1.13e-05	6.87e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—PLA2G6—melanoma	1.13e-05	6.87e-05	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—APC—melanoma	1.13e-05	6.86e-05	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—PIK3CG—melanoma	1.13e-05	6.86e-05	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—KIT—melanoma	1.13e-05	6.86e-05	CbGpPWpGaD
Gliclazide—ABCC8—Metabolism—PTGS2—melanoma	1.12e-05	6.82e-05	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—EGF—melanoma	1.12e-05	6.78e-05	CbGpPWpGaD
Gliclazide—KCNJ11—Metabolism—PIK3CB—melanoma	1.1e-05	6.67e-05	CbGpPWpGaD
Gliclazide—KCNJ11—Metabolism—PTGS2—melanoma	1.09e-05	6.61e-05	CbGpPWpGaD
Gliclazide—ALB—Hemostasis—IGF1—melanoma	1.08e-05	6.54e-05	CbGpPWpGaD
Gliclazide—ALB—Metabolism of lipids and lipoproteins—PIK3CG—melanoma	1.07e-05	6.5e-05	CbGpPWpGaD
Gliclazide—ALB—Platelet activation, signaling and aggregation—PIK3CA—melanoma	1.07e-05	6.47e-05	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—BRAF—melanoma	1.06e-05	6.45e-05	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—IGF1—melanoma	1.03e-05	6.28e-05	CbGpPWpGaD
Gliclazide—ALB—Hemostasis—PIK3CD—melanoma	1.03e-05	6.28e-05	CbGpPWpGaD
Gliclazide—ALB—Metabolism of lipids and lipoproteins—PPARG—melanoma	1.03e-05	6.28e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—PLA2G6—melanoma	1.03e-05	6.26e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—VCAN—melanoma	1.02e-05	6.17e-05	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—MAP2K1—melanoma	1e-05	6.07e-05	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—PIK3CD—melanoma	9.93e-06	6.03e-05	CbGpPWpGaD
Gliclazide—ABCC8—Metabolism—PTEN—melanoma	9.79e-06	5.95e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CG—melanoma	9.61e-06	5.84e-05	CbGpPWpGaD
Gliclazide—ALB—Metabolism—CYP17A1—melanoma	9.54e-06	5.8e-05	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—FGF2—melanoma	9.51e-06	5.78e-05	CbGpPWpGaD
Gliclazide—KCNJ11—Metabolism—PTEN—melanoma	9.49e-06	5.77e-05	CbGpPWpGaD
Gliclazide—ALB—Metabolism of lipids and lipoproteins—PIK3CD—melanoma	9.41e-06	5.72e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism of lipids and lipoproteins—PPARG—melanoma	9.28e-06	5.63e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—VCAN—melanoma	9.26e-06	5.62e-05	CbGpPWpGaD
Gliclazide—ALB—Metabolism—GNA11—melanoma	9.01e-06	5.47e-05	CbGpPWpGaD
Gliclazide—ALB—Hemostasis—PIK3CB—melanoma	9.01e-06	5.47e-05	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—MDM2—melanoma	8.9e-06	5.4e-05	CbGpPWpGaD
Gliclazide—ALB—Metabolism—FASN—melanoma	8.82e-06	5.36e-05	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—ERBB2—melanoma	8.77e-06	5.33e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CG—melanoma	8.76e-06	5.32e-05	CbGpPWpGaD
Gliclazide—ALB—Platelet activation, signaling and aggregation—AKT1—melanoma	8.71e-06	5.29e-05	CbGpPWpGaD
Gliclazide—ALB—Metabolism—SLC5A5—melanoma	8.67e-06	5.27e-05	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—PIK3CB—melanoma	8.66e-06	5.26e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—CYP17A1—melanoma	8.57e-06	5.2e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism of lipids and lipoproteins—PPARG—melanoma	8.46e-06	5.14e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CD—melanoma	8.45e-06	5.13e-05	CbGpPWpGaD
Gliclazide—ALB—Metabolism—GNAQ—melanoma	8.38e-06	5.09e-05	CbGpPWpGaD
Gliclazide—ALB—Metabolism—CD44—melanoma	8.38e-06	5.09e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism of lipids and lipoproteins—ALB—melanoma	8.34e-06	5.07e-05	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—CXCL8—melanoma	8.32e-06	5.05e-05	CbGpPWpGaD
Gliclazide—ALB—Hemostasis—IL2—melanoma	8.28e-06	5.03e-05	CbGpPWpGaD
Gliclazide—ALB—Metabolism of lipids and lipoproteins—PIK3CB—melanoma	8.2e-06	4.98e-05	CbGpPWpGaD
Gliclazide—ALB—Metabolism of lipids and lipoproteins—PTGS2—melanoma	8.13e-06	4.94e-05	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—CDKN1B—melanoma	8.12e-06	4.93e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—GNA11—melanoma	8.09e-06	4.91e-05	CbGpPWpGaD
Gliclazide—ALB—Metabolism—CYP1B1—melanoma	8.03e-06	4.88e-05	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—CASP3—melanoma	7.96e-06	4.84e-05	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—IL2—melanoma	7.95e-06	4.83e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—FASN—melanoma	7.92e-06	4.81e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—CYP17A1—melanoma	7.81e-06	4.74e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—SLC5A5—melanoma	7.79e-06	4.73e-05	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—CCND1—melanoma	7.75e-06	4.71e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CD—melanoma	7.7e-06	4.68e-05	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—CTNNB1—melanoma	7.67e-06	4.66e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism of lipids and lipoproteins—ALB—melanoma	7.6e-06	4.62e-05	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—MMP9—melanoma	7.52e-06	4.57e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—CD44—melanoma	7.52e-06	4.57e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—GNAQ—melanoma	7.52e-06	4.57e-05	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—CDKN1A—melanoma	7.5e-06	4.55e-05	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—PTEN—melanoma	7.48e-06	4.54e-05	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—NFKB1—melanoma	7.44e-06	4.52e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—GNA11—melanoma	7.38e-06	4.48e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CB—melanoma	7.36e-06	4.47e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—melanoma	7.3e-06	4.43e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—FASN—melanoma	7.22e-06	4.38e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—CYP1B1—melanoma	7.21e-06	4.38e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—SLC5A5—melanoma	7.1e-06	4.31e-05	CbGpPWpGaD
Gliclazide—ALB—Metabolism of lipids and lipoproteins—PTEN—melanoma	7.09e-06	4.31e-05	CbGpPWpGaD
Gliclazide—ALB—Hemostasis—VEGFA—melanoma	7.03e-06	4.27e-05	CbGpPWpGaD
Gliclazide—ALB—Hemostasis—NRAS—melanoma	6.95e-06	4.22e-05	CbGpPWpGaD
Gliclazide—ABCC8—Metabolism—PIK3CA—melanoma	6.91e-06	4.2e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—GNAQ—melanoma	6.86e-06	4.16e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—CD44—melanoma	6.86e-06	4.16e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CB—melanoma	6.71e-06	4.08e-05	CbGpPWpGaD
Gliclazide—KCNJ11—Metabolism—PIK3CA—melanoma	6.7e-06	4.07e-05	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—STAT3—melanoma	6.69e-06	4.06e-05	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—NRAS—melanoma	6.67e-06	4.05e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—melanoma	6.65e-06	4.04e-05	CbGpPWpGaD
Gliclazide—ALB—Hemostasis—MAPK3—melanoma	6.65e-06	4.04e-05	CbGpPWpGaD
Gliclazide—ALB—Metabolism—ABCB1—melanoma	6.61e-06	4.02e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—CYP1B1—melanoma	6.57e-06	3.99e-05	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—MAPK3—melanoma	6.39e-06	3.88e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism of lipids and lipoproteins—PTEN—melanoma	6.36e-06	3.86e-05	CbGpPWpGaD
Gliclazide—ALB—Hemostasis—MAPK1—melanoma	6.33e-06	3.84e-05	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—MYC—melanoma	6.22e-06	3.78e-05	CbGpPWpGaD
Gliclazide—ALB—Metabolism—PRKCA—melanoma	6.09e-06	3.7e-05	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—MAPK1—melanoma	6.08e-06	3.69e-05	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—EGFR—melanoma	6.08e-06	3.69e-05	CbGpPWpGaD
Gliclazide—ALB—Metabolism—ERCC2—melanoma	6.04e-06	3.67e-05	CbGpPWpGaD
Gliclazide—ALB—Hemostasis—KRAS—melanoma	5.98e-06	3.63e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—ABCB1—melanoma	5.94e-06	3.61e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—melanoma	5.8e-06	3.52e-05	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—KRAS—melanoma	5.74e-06	3.49e-05	CbGpPWpGaD
Gliclazide—ABCC8—Metabolism—AKT1—melanoma	5.64e-06	3.43e-05	CbGpPWpGaD
Gliclazide—ALB—Hemostasis—PIK3CA—melanoma	5.49e-06	3.34e-05	CbGpPWpGaD
Gliclazide—KCNJ11—Metabolism—AKT1—melanoma	5.47e-06	3.32e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—PRKCA—melanoma	5.46e-06	3.32e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—ERCC2—melanoma	5.42e-06	3.29e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—ABCB1—melanoma	5.41e-06	3.29e-05	CbGpPWpGaD
Gliclazide—ALB—Hemostasis—TP53—melanoma	5.31e-06	3.23e-05	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—PIK3CA—melanoma	5.28e-06	3.2e-05	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—TP53—melanoma	5.1e-06	3.1e-05	CbGpPWpGaD
Gliclazide—ALB—Hemostasis—HRAS—melanoma	5.08e-06	3.09e-05	CbGpPWpGaD
Gliclazide—ALB—Metabolism of lipids and lipoproteins—PIK3CA—melanoma	5e-06	3.04e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—PRKCA—melanoma	4.98e-06	3.03e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—ERCC2—melanoma	4.94e-06	3e-05	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—HRAS—melanoma	4.88e-06	2.97e-05	CbGpPWpGaD
Gliclazide—ALB—Metabolism—PIK3CG—melanoma	4.77e-06	2.9e-05	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—IL6—melanoma	4.67e-06	2.84e-05	CbGpPWpGaD
Gliclazide—ALB—Metabolism—PPARG—melanoma	4.6e-06	2.79e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CA—melanoma	4.49e-06	2.73e-05	CbGpPWpGaD
Gliclazide—ALB—Hemostasis—AKT1—melanoma	4.49e-06	2.73e-05	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—AKT1—melanoma	4.31e-06	2.62e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—PIK3CG—melanoma	4.28e-06	2.6e-05	CbGpPWpGaD
Gliclazide—ALB—Metabolism—PIK3CD—melanoma	4.19e-06	2.55e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—PPARG—melanoma	4.13e-06	2.51e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—melanoma	4.09e-06	2.49e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—PIK3CG—melanoma	3.9e-06	2.37e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—PPARG—melanoma	3.77e-06	2.29e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—PIK3CD—melanoma	3.76e-06	2.29e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—ALB—melanoma	3.71e-06	2.26e-05	CbGpPWpGaD
Gliclazide—ALB—Metabolism—PIK3CB—melanoma	3.65e-06	2.22e-05	CbGpPWpGaD
Gliclazide—ALB—Metabolism—PTGS2—melanoma	3.62e-06	2.2e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—PIK3CD—melanoma	3.43e-06	2.08e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—ALB—melanoma	3.39e-06	2.06e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—PIK3CB—melanoma	3.28e-06	1.99e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—PTGS2—melanoma	3.25e-06	1.97e-05	CbGpPWpGaD
Gliclazide—ALB—Metabolism—PTEN—melanoma	3.16e-06	1.92e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—PIK3CB—melanoma	2.99e-06	1.82e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—PTGS2—melanoma	2.96e-06	1.8e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—PTEN—melanoma	2.83e-06	1.72e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—PTEN—melanoma	2.58e-06	1.57e-05	CbGpPWpGaD
Gliclazide—ALB—Metabolism—PIK3CA—melanoma	2.23e-06	1.35e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—PIK3CA—melanoma	2e-06	1.21e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—PIK3CA—melanoma	1.82e-06	1.11e-05	CbGpPWpGaD
Gliclazide—ALB—Metabolism—AKT1—melanoma	1.82e-06	1.11e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—AKT1—melanoma	1.63e-06	9.92e-06	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—AKT1—melanoma	1.49e-06	9.04e-06	CbGpPWpGaD
